Marksans Pharma Limited · NSE:MARKSANS
Marksans Pharma — Q1 FY2026 Earnings Presentation
48 slides from Marksans Pharma's earnings presentation, Aug 12, 2025
Slide 1: Cover letter to stock exchanges
Date: August 12, 2025 BSE Limited National Stock Exchange of India Limited Corporate Relation Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block-G, Dalal Street, Bandra-Kurla Complex, Mumbai - 400001. Bandra (East), Mumbai - 400051. Scrip Code: 524404 Symbol: MARKSAN
Slide 2: Earnings Presentation Q1FY26
Earnings Presentation Q1FY26 12th August 2025 BSE: 524404 | NSE: MARKSANS | ISIN: INE750C01026 ©2025 – Marksans Pharma Ltd., All Rights Reserved www.marksanspharma.com
Slide 3: Safe Harbor
Safe Harbor This presentation has been prepared by Marksans Pharma Limited (the “Company”) solely for informational purposes. The information contained herein is not intended to be comprehensive and should not be relied upon as the sole basis for any investment or business decision. This presentatio
Slide 4: Table of Contents
04 Q1FY26 Financial and Business Highlights 15 Marksans Pharma at a Glance Table of 20 Marksan’s Journey Contents 27 Strategic Initiatives 35 Sustainability at Marksans 45 Annexure www.marksanspharma.com Page 3
Slide 5: Q1FY26 Financial & Business Highlights
Q1FY26 Financial & Business Highlights www.marksanspharma.com Page 4
Slide 6: Management Commentary
Management Commentary Mark Saldanha “While Q1FY26 was a seasonally soft quarter, we delivered year-on-year revenue growth of 5%, while gross profit increased by 8.9%. This was supported by successful new product launches in the M A N A G I N G D I R E C TO R A N D C E O US markets and the easing of
Slide 7: Financial Highlights Q1FY26 – YoY Performance
Financial Highlights Q1FY26 – YoY Performance Q1FY26 Q1FY25 YoY Growth % YoY Performance • Driven mainly by growth in the US market from new Revenue ₹ 620.0 cr ₹ 590.6 cr 5.0% product launches in the gastrointestinal, pain management, and digestive health segments • Gross margin improved with liquid
Slide 8: Financial Highlights Q1FY26 – QoQ Performance
Financial Highlights Q1FY26 – QoQ Performance Q1FY26 Q4FY25 QoQ Growth % QoQ Performance • Softer demand due to seasonal headwinds. Q2 has Revenue ₹ 620.0 cr ₹ 708.5 cr 12.5% already started showing signs of revival Gross Profit ₹ 358.2 cr ₹ 383.2 cr • Margins improvement was driven by better 6.5% p
Slide 9: Financial & Other Highlights – Q1FY26
Financial & Other Highlights – Q1FY26 Revenue Contribution for Q1FY26: US - ₹ 327.6 cr | UK & Europe - ₹ 203.8 cr | Australia & New Zealand - ₹ 57.0 cr |RoW - ₹ 31.6 cr Research & Development (R&D) spends at ₹ 12.1 cr in Q1FY26, 2.0% of consolidated revenue Cash generated from operations at ₹ 48.7 c
Slide 10: Revenue by Segment and Geography
Revenue by Segment and Geography FY25 Q1 FY26 Revenue by Segment Revenue by Geography US & North America UK & Europe ₹ 327.6 cr ₹ 203.8 cr 31% YoY 19% YoY Rx 25.9% 52.8% 32.9% OTC 74.1% 5.1% OTC Rx 9.2% RoW - ₹ 31.6 cr 39% YoY Australia & New Zealand Our OTC segment grew at a CAGR of ₹ 57.0 cr 21% (
Slide 11: Quarterly Financial Trends
Quarterly Financial Trends Operating Revenue (₹ cr) Gross Profit (₹ cr) & Gross Margin (%) 709 682 410 390 384 384 383 642 358 620 370 60.00% 591 329 350 59.7% 57.8% 330 310 56.2% 54.1% 290 270 55.7% 250 40.00% Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 EBITDA (₹ cr) & EBI
Slide 12: US & North America Q1FY26 Performance
US & North America Q1FY26 Performance Quarterly Performance (₹ cr) 52.8% 353 329 328 304 251 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Revenue US Overview 30.6% YoY 0.3% QoQ ₹ 327.6 cr • US & North America is a key growth market • The Company services this region through Time Cap Labs Inc., its wholly owne
Slide 13: UK & Europe Q1FY26 Performance
UK & Europe Q1FY26 Performance Quarterly Performance (₹ cr) 32.9% 274 252 247 258 204 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Revenue UK Overview 19.0% YoY 25.7% QoQ ₹ 203.8 cr • Top 5 Indian pharmaceutical firms in the UK in terms of revenue • The Company services this region through its wholly owned su
Slide 14: Australia & New Zealand Q1FY26 Performance
Australia & New Zealand Q1FY26 Performance Quarterly Performance (₹ cr) 9.2% 77 66 64 57 47 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Revenue Australia & New Zealand Overview 13.1% YoY 25.5% QoQ ₹ 57.0 cr • In 2005, Marksans acquired 60% stake in Nova to have an established base in Australia • Nova is enga
Slide 15: RoW Business Q1FY26 Performance
RoW Business Q1FY26 Performance Quarterly Performance (₹ cr) 32 29 28 23 24 5.1% Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Revenue RoW Overview 39.4% YoY 7.9% QoQ ₹ 31.6 cr • RoW segment encompasses 10 countries, spanning across CIS and MENA regions • Marksans acquired 100% stake in Access Healthcare in Du
Slide 16: Marksans Pharma at a Glance
Marksans Pharma at a Glance www.marksanspharma.com Page 15
Slide 17: Company Overview
Company Overview CFO of ₹ 2,623 cr 20.3% ₹ 48.7 cr 4 300+ FY25 Revenue FY25 in Q1FY26 4 Manufacturing Products (OTC: 78.8%, EBITDA Margin Cash balance : ₹ 711 cr Units & and 1,500+ SKUs Rx: 21.2%) (as of June 2025) 4 R&D Centers $100+mn Amongst Accreditations 2,000+ in US Top 5 USFDA, UK MHRA, Total
Slide 18: Marksan's OTC Focus
Marksan’s OTC Focus Marksan’s OTC Portfolio Industry Opportunity According to IQVIA, Global OTC Market size is The OTC business includes store brands, private projected to be $204 bn in 2025 label manufacturing for retailers and customers Prescription (Rx) to over-the-counter (OTC) It also m
Slide 19: Manufacturing Capabilities
Manufacturing Capabilities Manufacturing Facility in Farmingdale, USA Total Capacity : 26 bn units p.a.* • Manufactures hard gels, tablets and capsules • Spread over an area of 7000 sq. mt. USA • "Made in the USA” product offering • Added incremental packaging lines Manufacturing Facility in Southpo
Slide 20: R&D Capabilities
R&D Capabilities R&D (₹ cr) and R&D % to sales 1.5% 2.0% 1.6% 1.6% 2.2% 2.0% 1.4% 0.6% 0.6% 0.7% 58 R&D Southport, Farmingdale, United Kingdom Navi Mumbai, United States India 30 29 35 Goa, India Centers 19 15 12 5 5 8 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 Q1FY26 Continued focus on R&D Plans
Slide 21: Marksan's Journey
Marksan’s Journey www.marksanspharma.com Page 20
Slide 22: Our Key Events
Our Key Events • Raised ₹ 372.40 cr in Increased focus on OTC equity via conversion segment in US market OTC Segment’s Spun off into a separate of warrants issued to entity - Glenmark OrbiMed and Revenue crossed ₹ • Acquired Bells, Sons & Promoters 2,000 cr revenue Laboratories Ltd. Co. (Druggists)
Slide 23: Growth and Achievements Since 2017
Growth and Achievements Since 2017 Revenue OTC Revenue Consistent and Consistent Manufacturing growth growth of meaningfully growth in cash capacity SKUs ~3.4x to ~4.6x to high EBITDA from increased from 6 growth of margin operations over ~75% to 1500+ ₹ 2,623 cr ₹ 2,066 cr the years bn units p.a. e
Slide 24: Financial Trends – High Growth Trajectory
Financial Trends – High Growth Trajectory Operating Revenue (₹ cr) EBITDA (₹ cr) & EBITDA Margin (%) 3,000.0 2,623 600.00 30.0% 24.7% 20.3% 21.1% 2,177 2,500.0 500.00 25.0% 17.4% 2,000.0 1,852 18.3% 400.00 17.0% 20.0% 1,491 1,500.0 1,376 13.2% 1,134 300.00 8.6% 15.0% 1,005 5.8% 533 912 459 1,000.0 7
Slide 25: Financial Trends – High Growth Trajectory
Financial Trends – High Growth Trajectory Total Assets (₹ cr) Net Debt to EBITDA 3,500.0 3,240 2.0x 1.6x 3,000.0 2,681 1.5x 1.0x 2,190 0.5x 1.0x 2,500.0 0.5x 1,640 2,000.0 0.0x 1,500.0 1,228 -0.5x 897 -0.4x 1,000.0 752 732 804 -1.0x -0.6x -1.2x -1.5x -1.3 -1.5x 500.0 -2.0x 0.0 -2.5x -2.0x FY17 FY18
Slide 26: Proven Success in Acquisitions
Proven Success in Acquisitions Acquisitions Acquired manufacturing unit in Goa from Teva Pharma United United Target Country Australia United States UAE India Kingdom Kingdom Transaction December 31, March 24, 2006 August 27, 2008 June 30, 2015 April 25, 2022 April 19, 2023 Date 2007 Sales growth fr
Slide 27: 2 Year Shareholder Return
2 Year Shareholder Return 2 Year Shareholder Return Marksans Nifty Pharma 287 160 Jun-23 Aug-23 Oct-23 Dec-23 Feb-24 Apr-24 Jun-24 Aug-24 Oct-24 Dec-24 Feb-25 Apr-25 Jun-25 Annual Dividends ~187% share price increase in last 2 years FY24: Dividend of ₹ 0.6 per equity share FY25: Dividend of ₹ 0.8 pe
Slide 28: Strategic Initiatives
Strategic Initiatives www.marksanspharma.com Page 27
Slide 29: Core Strategies for Future Growth
Core Strategies for Future Growth To become the most reliable partner in the consumer healthcare space Focus on store brand OTC Segment • Expanding within proven OTC demand areas, expanding market share with customers and key regions. Aim to capture a significant part of the multi-billion-dollar OTC
Slide 30: Capturing OTC Opportunity
Capturing OTC Opportunity Global Category Value Share ($ bn) Expanding OTC Business Value Share Capture multi- • Marksans competes in large and billion-dollar OTC growing categories Cough and Cold 44 opportunity • Increasing store brand penetration in Vitamins and Tonics 36 Strengthening North Ameri
Slide 31: Product Pipeline
Product Pipeline Continued focus on R&D leading to strong product pipeline and successful launches UK US Australia & New Zealand Rest of the World • 12 products approved • 58 products/SKUs • 3 products approved • 44 products approvals • 18 products filed during commercialized • 3 products filed duri
Slide 32: Key Product Launches in Last 2 Years
Key Product Launches in Last 2 Years Brand COMPOSITION Therapy Segment Market OMEPRAZOLE OMEPRAZOLE DELAYED-RELEASE TABLETS, 20 MG Gastrointestinal US OXYBUTYNIN HYDROCHLORIDE OXYBUTYNIN HYDROCHLORIDE 2.5MG/5ML ORAL SOLUTION Central Nervous System (CNS) UK METFORMIN HYDROCHLORIDE METFORMIN HYDROCHLO
Slide 33: Strong Balance Sheet to Drive Inorganic Growth
Strong Balance Sheet to Drive Inorganic Growth Cash balance of ₹ 711 cr as of 30th June 2025. Cash positive for over 5 years. Low financial risk Consistent cash generation. ₹ 48.7 cr in Q1FY26 Driving inorganic growth. Evaluating acquisitions in Europe Disciplined capital allocation region for front
Slide 34: We've Delivered What We Promised
We’ve Delivered What We Promised How have we S.no Marksans Guidance performed? 01 Revenue guidance of ₹ 2,000 cr Achieved 02 Focus on expanding OTC business – ~4.6x revenue growth since 2017 Achieved Disciplined capital allocation approach - Effectively utilizing the cash through buyback, 03 Achieve
Slide 35: Growth: FY26 and Beyond
Growth: FY26 and Beyond Disciplined efforts to become future ready Strategic Roadmap • Doubling low-cost manufacturing capacity in India from • High growth in revenues and margin. Aim to reach 8bn to 16bn units. Total manufacturing capacity of revenue of ₹ 3,000 cr in next 2 years Marksans is 26bn u
Slide 36: Sustainability at Marksans
Sustainability at Marksans www.marksanspharma.com Page 35
Slide 37: Driving Sustainable Progress
Driving Sustainable Progress Environment Social Governance Ensure sustainability in our Positively impact our people Bring about an industry operations and projects by and community through utmost transformation by leading ethically positively impacting the natural respect for human rights, and bols
Slide 38: Empowering Communities
Empowering Communities 01 02 03 04 05 Health Care Education Farming and Plantation Food Distribution Overall wellbeing of women • Organized free health • Donations towards • Tree plantation in Verna • Distribution of free food and children check-up camps and construction of new Industrial Estate, Go
Slide 39: Sustainability Goals and Progress
Sustainability Goals and Progress Sustainability Pillars Goal Initial Milestone Status Reduction of annual virgin • Use of 100% recyclable HDPE/ PET plastic usage in packaging bottles/ LDPE Shrink wrapping in collaboration with • Use of 70-80% recyclable labels suppliers and customers In Progress Go
Slide 40: Sustainability Goals and Progress
Sustainability Goals and Progress Sustainability Pillars Goal Initial Milestone Status Focus on areas of • Mobile health care units to support • 2% of the net profit is preventive healthcare, the grievances of communities in spent for overall development of the education, eradicating around 20-25 vi
Slide 41: Sustainability Goals and Progress
Sustainability Goals and Progress Sustainability Pillars Goal Initial Milestone Status By 2028, we plan to achieve • Waste disposal with co-processing – • In Progress sustainable waste disposal Recycled and Reused • Use of renewable/ methods • 100% Waste water utilization after recyclable sources of
Slide 42: Corporate Governance Principles
Corporate Governance Principles Conducting Business in Ethical, Business continues to create value for Transparent and Accountable manner customers and consumers responsibly Producing goods which have Application of Best a sustainable life cycle management practices Adherence to ethical working stan
Slide 43: Board of Directors - Guided By Visionary Minds
Board of Directors - Guided By Visionary Minds Mark Saldanha Sandra Saldanha Varddhman Jain Dr. Sunny Sharma Founder, Chairman & Promoter, Whole-Time Director Non-Executive Director Managing Director Whole-Time Director • Science Graduate • MA in Arts (Sociology) • M. Pharm (Pharmaceuticals) • MBA,
Slide 44: Board of Directors - Guided By Visionary Minds
Board of Directors - Guided By Visionary Minds Abhinna Sundar Mohanty Digant Mahesh Parikh Shailaja Vardhan Mr. Srinivas Mishra Independent Director Independent Director Independent Director Independent Director • M.Sc., Mathematics • MBA, Finance • Seasoned professional in • B. Sc Hons (Mathematics
Slide 45: Experienced Leadership Team
Experienced Leadership Team Mark Saldanha Varddhman Jain Sathish Kumar Anjani Kumar David Mohammed Jitendra M Sharma Founder, Chairman & Whole-Time Director MD – Marksans Pharma COO – Global Operations MD – Pharmaceuticals Chief Financial Officer Managing Director UK Ltd. and USA Australasia Pty Ltd
Slide 46: Annexure
Annexure www.marksanspharma.com Page 45
Slide 47: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Particulars (₹ cr) Q1FY26 Q1FY25 Q4FY25 YoY QoQ FY25 Operating Revenue 620.0 590.6 708.5 5.0% -12.5% 2,622.8 Gross Profit 358.2 328.8 383.2 8.9% -6.5% 1,479.1 Gross Margin % 57.8% 55.7% 54.1% 209 bps 368 bps 56.4% EBITDA 100.1 128.4 126.9 -22.0% -21.1% 532.7 EBIT
Slide 48: Thank You
Thank You For more information please contact: Jitendra Sharma (CFO) Corporate Office Marksans Pharma Ltd. 11th Floor Grandeur, Off Veera Desai Road, Tel: +91 22 4001-2000 jitendra@marksanspharma.com Opp Gundecha Symphony, Andheri (W), Mumbai – 400 053, Maharashtra - India © 2025 Marksans Pharma Ltd